Timing of Live Attenuated Vaccination in Infants Exposed to Infliximab or Adalimumab in Utero : A Prospective Cohort Study in 107 Children

For infants exposed in utero to anti-tumour necrosis factor-α [TNF] medications, it is advised that live-attenuated vaccinations be postponed until the drug is cleared, but little is known about time to clearance. To minimize delays before live-attenuated vaccination can be given, we aimed to develo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2022-12, Vol.16 (12), p.1835-1844
Main Authors: Liu, Zheng, Julsgaard, Mette, Zhu, Xiao, Martin, Jennifer, Barclay, Murray L, Cranswick, Noel, Gibson, Peter R, Gearry, Richard B, van der Giessen, Janine, Connor, Susan J, Rosella, Ourania, Grosen, Anne, Toong, Catherine, Flanagan, Emma, Wieringa, Jantien W, Janneke van der Woude, C, Bell, Sally J, Kanis, Shannon, Fallingborg, Jan, Hvas, Christian L, Christensen, Lisbet A, Connell, William R, Brown, Steven J, Kjeldsen, Jens, Wildt, Signe, Svenningsen, Lise, Sparrow, Miles P, Walsh, Alissa, Radford-Smith, Graham, Lawrance, Ian C, Andrews, Jane M, Ellard, Kathrine
Format: Article
Language:English
Subjects:
Adalimumab - therapeutic use
Bayes Theorem
Child
Female
Humans
Infant
Infant, Newborn
Inflammatory Bowel Diseases - drug therapy
Infliximab - therapeutic use
Maternal Exposure
Pregnancy
Prospective Studies
Tumor Necrosis Factor Inhibitors - therapeutic use
Vaccination
Vaccines, Attenuated - administration & dosage
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!